TG THERAPEUTICS, INC. Form 8-K June 01, 2015

# **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

\_\_\_\_\_

FORM 8-K

**CURRENT REPORT** 

Pursuant to Section 13 or 15(d) of the

**Securities Exchange Act of 1934** 

Date of report (Date of earliest event reported): May 31, 2015

**TG Therapeutics, Inc.** 

(Exact Name of Registrant as Specified in Charter)

Delaware 001-32639 36-3898269

(State or Other Jurisdiction (Commission File Number) (IRS Employer Identification No.)

of Incorporation)

# 3 Columbus Circle, 15th Floor


#### New York, New York 10019

(Address of Principal Executive Offices)

#### (212) 554-4484

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act. Soliciting material pursuant to Rule 14a-12 under the Exchange Act. Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

## Item 8.01. Other Events.

On May 31, and June 1, 2015, TG Therapeutics, Inc. (the "Company") issued press releases announcing certain data regarding its clinical studies of TGR-1202, TG-1101 in combination with TGR-1202, and TG-1101 in combination with TGR-1202 and ibrutinib, respectively. Copies of the press releases are being filed as Exhibits 99.1 and 99.2 and incorporated in this Item by reference. In addition, the Company hosted an analyst and investor event on Sunday, May 31st, 2015 with formal presentations from Nathan Fowler, MD, with MD Anderson Cancer Center, Anthony Mato, MD, with University of Pennsylvania and Owen O'Connor, MD, PhD, with Columbia University Medical Center. A copy of the presentation from the event is being filed as Exhibit 99.3 and incorporated in this Item by reference.

# Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated May 31, 2015.

99.2 Press Release, dated June 1, 2015.

99.3 Investor and Analyst Event Presentation, dated May 31, 2015

-2-

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TG Therapeutics, Inc.** (Registrant)

Date: June 1, 2015 By: /s/ Sean A. Power Sean A. Power

Chief Financial Officer

-3-

# INDEX TO EXHIBITS

Exhibit <u>Number</u><u>Description</u>

99.1	Press Release, dated May 31, 2015.
99.2	Press Release, dated June 1, 2015.

99.3 Investor and Analyst Event Presentation, dated May 31, 2015

-4-